Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if a reduction in the enzyme 1-hydroxylase, which activates Vitamin D, is the cause of overactivity of the parathyroid glands (called secondary hyperparathyroidism - normal blood calcium and elevated parathyroid hormone) in a selected group of young patients with normal kidney function.

Detailed Description
-----------------
Vitamin D, an essential nutrient, is produced by the skin after sunlight shines on it. Vitamin D must then be activated by both the liver and the kidneys to perform its function of maintaining strong bones and helping to prevent heart disease, infection, diabetes and cancer. Reduced kidney activation of Vitamin D occurs with advanced age and with all kidney diseases. We have identified a small group of patients who appear to have reduced ability of the kidneys to activate vitamin D, even though they are young and do not have chronic kidney disease. In these patients, we are comparing the ability of their kidneys to activate Vitamin D to that of healthy controls. To stimulate the kidneys to activate Vitamin D, we are giving parathyroid hormone intravenously over 8 hours and collecting blood and urine at baseline, 4 and 8 hours. This type of parathyroid infusion does not cause side effects. The gene that controls this activation is also being studied (by a simple blood test) to look for abnormalities. We are now actively recruiting healthy controls for this study.

Official Title
-----------------
Clinical and Molecular Characterization of Suspected Partial 25-hydroxyvitamin D-1-alpha-hydroxylase Deficiency

Conditions
-----------------
Secondary Hyperparathyroidism

Intervention / Treatment
-----------------
* Drug: Teriparatide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Caucasian female Age 40-59 years Serum creatinine < 1.3 and estimated glomerular filtration rate (GRF) > 60 Serum calcium in the normal range (for U Md lab 8.6-10 mg/dl) Parathyroid hormone in the normal range (for U Md lab 12-54 pg/ml) Normal 25-hydroxyvitamin D level (30 ng/ml or higher) For women of childbearing age, non-pregnant (based on negative urine pregnancy test on the morning of the teriparatide infusion) Exclusion Criteria: Non-caucasian Age under 40 and over 59 years Male Serum creatinine over 1.3 or estimated glomerular filtration rate (GFR) < 60 Abnormal serum calcium (for U Md lab, below 8.6 or above 10 mg/dl) Abnormal parathyroid hormone (for U Md lab, above 65 or below 12 pg/ml) For women of childbearing age, non-pregnant (based on urine pregnancy test on the morning of the teriparatide infusion) History of bone radiation History of Paget disease of bone History of bone malignancy or metastases History of allergy or sensitivity to Forteo

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 59 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: teriparatide control<br>control subject | Drug: Teriparatide<br>* Teriparatide will be given by continuous intravenous infusion at a rate of 12 pmol/kg/hr for 8 hours to both patients and controls<br>* Other names: Forteo;|
| Experimental: Teriparatide Patient<br>Patient with secondary hyperparathyroidism | Drug: Teriparatide<br>* Teriparatide will be given by continuous intravenous infusion at a rate of 12 pmol/kg/hr for 8 hours to both patients and controls<br>* Other names: Forteo;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Level of Activated Vitamin D (1,25-dihydroxyvitamin D) After Parathyroid Hormone Infusion at Baseline, 4 and 8 Hours | 1,25-D was measured at baseline, 4 and 8 hours after PTH infusion | baseline, 4 and 8 hours after start of infusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Number of Patients With Mutations in CYP27B1 | CYP27B1 gene (the gene for 25-hydroxyvitamin D-1-alpha hydroxylase) was sequenced for all in patient group and compared with published control data | blood samples taken at baseline and sequenced over several days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hyperparathyroidism, parathyroid, vitamin D, vitamin D deficiency